Department of Pharmacy, Changyi People's Hospital, Weifang City, Shandong Province, China.
Outpatient Office, Changyi People's Hospital, Shandong Province, China.
J Coll Physicians Surg Pak. 2021 Nov;31(11):1375-1377. doi: 10.29271/jcpsp.2021.11.1375.
This study was conducted to investigate the influence of μ-opioid receptor gene (OPRM1) A118G polymorphism on dosage of morphine in advanced liver cancer patients. Seventy patients with advanced liver cancer at Changyi People's Hospital, Shandong Province, China, were included from February 2019 to December 2020. The dosage of morphine in patients with OPRM1 A118G different genotypes was compared. Thirty patients (42.86%) were of AA genotype, 35 (50.00%) were AG genotype and 5 (7.14%) were GG genotype. There was a significant difference in morphine dosage within the first 24 hours in patients with AA, AG and GG genotypes (all p <0.001), and morphine dosage in patients with GG genotype was the highest. In conclusion, OPRM1 A118G genotype may affect the dosage of morphine in advanced liver cancer patients. More dosages of morphine are needed for pain control in patients with G allele. Key Words: μ-opioid receptor gene (OPRM1), Gene polymorphism, Liver cancer, Morphine.
本研究旨在探讨μ-阿片受体基因（OPRM1）A118G 多态性对晚期肝癌患者吗啡剂量的影响。
选取 2019 年 2 月至 2020 年 12 月山东省昌邑市人民医院收治的 70 例晚期肝癌患者为研究对象，比较 OPRM1 A118G 不同基因型患者的吗啡剂量。
70 例患者中，AA 基因型 30 例（42.86%），AG 基因型 35 例（50.00%），GG 基因型 5 例（7.14%）。AA、AG 和 GG 基因型患者在 24 小时内吗啡剂量差异有统计学意义（均 P<0.001），且 GG 基因型患者的吗啡剂量最高。
OPRM1 A118G 基因型可能影响晚期肝癌患者吗啡的剂量。携带 G 等位基因的患者需要更高剂量的吗啡来控制疼痛。
μ-阿片受体基因（OPRM1）；基因多态性；肝癌；吗啡
